Accessibility to allogeneic hematopoietic cell transplantation (HCT) programs for older patients is growing constantly. We report on the clinical outcomes of a group of 701 adults aged & GE;70 years, with acute myeloid leukemia (AML) in first complete remission (CR1), who received a first HCT, from HLA-matched sibling donors (MSD), 10/10 HLA-matched unrelated donors (UD), 9/10 HLA-mismatched unrelated donors (mUD) or haploidentical (Haplo) donors. The 2-year overall survival (OS) was 48.1%, leukemia-free survival (LFS) 45.3%, relapse incidence (RI) 25.2%, non-relapse mortality (NRM) 29.5% and GVHD-free, relapse-free survival (GRFS), 33.4%. Compared to MSD, patients transplanted from Haplo and UD presented lower RI (HR 0.46, 95% CI 0.25-0.8, p = 0.02 and HR 0.44, 95% CI: 0.28-0.69, p = 0.001, respectively); this translated into prolonged LFS for Haplo (HR 0.62, 95% CI: 0.39-0.99, p = 0.04). Patients transplanted from mUD exhibited the highest NRM incidence (HR 2.33, 95% CI: 1.26-4.31, p = 0.007). HCT in selected adult CR1 AML patients >70 years is feasible and could be associated with good clinical outcomes. Prospective clinical trials are warranted.

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) / Maffini, Enrico; Ngoya, Maud; Galimard, Jacques-Emmanuel; Harbi, Samia; Kröger, Nicolaus; Platzbecker, Uwe; Sengeloev, Henrik; Craddock, Charles; Potter, Victoria; Choi, Goda; Chevallier, Patrice; Stölzel, Friedrich; Tholouli, Eleni; Maertens, Johan; Ciceri, Fabio; Cornelissen, Jan; Sanz, Jaime; Spyridonidis, Alexandros; Lanza, Francesco; Nagler, Arnon; Mohty, Mohamad. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - ELETTRONICO. - 58:9(2023), pp. 1033-1041. [10.1038/s41409-023-02027-y]

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Lanza, Francesco
Membro del Collaboration Group
;
2023

Abstract

Accessibility to allogeneic hematopoietic cell transplantation (HCT) programs for older patients is growing constantly. We report on the clinical outcomes of a group of 701 adults aged & GE;70 years, with acute myeloid leukemia (AML) in first complete remission (CR1), who received a first HCT, from HLA-matched sibling donors (MSD), 10/10 HLA-matched unrelated donors (UD), 9/10 HLA-mismatched unrelated donors (mUD) or haploidentical (Haplo) donors. The 2-year overall survival (OS) was 48.1%, leukemia-free survival (LFS) 45.3%, relapse incidence (RI) 25.2%, non-relapse mortality (NRM) 29.5% and GVHD-free, relapse-free survival (GRFS), 33.4%. Compared to MSD, patients transplanted from Haplo and UD presented lower RI (HR 0.46, 95% CI 0.25-0.8, p = 0.02 and HR 0.44, 95% CI: 0.28-0.69, p = 0.001, respectively); this translated into prolonged LFS for Haplo (HR 0.62, 95% CI: 0.39-0.99, p = 0.04). Patients transplanted from mUD exhibited the highest NRM incidence (HR 2.33, 95% CI: 1.26-4.31, p = 0.007). HCT in selected adult CR1 AML patients >70 years is feasible and could be associated with good clinical outcomes. Prospective clinical trials are warranted.
2023
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) / Maffini, Enrico; Ngoya, Maud; Galimard, Jacques-Emmanuel; Harbi, Samia; Kröger, Nicolaus; Platzbecker, Uwe; Sengeloev, Henrik; Craddock, Charles; Potter, Victoria; Choi, Goda; Chevallier, Patrice; Stölzel, Friedrich; Tholouli, Eleni; Maertens, Johan; Ciceri, Fabio; Cornelissen, Jan; Sanz, Jaime; Spyridonidis, Alexandros; Lanza, Francesco; Nagler, Arnon; Mohty, Mohamad. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - ELETTRONICO. - 58:9(2023), pp. 1033-1041. [10.1038/s41409-023-02027-y]
Maffini, Enrico; Ngoya, Maud; Galimard, Jacques-Emmanuel; Harbi, Samia; Kröger, Nicolaus; Platzbecker, Uwe; Sengeloev, Henrik; Craddock, Charles; Potter, Victoria; Choi, Goda; Chevallier, Patrice; Stölzel, Friedrich; Tholouli, Eleni; Maertens, Johan; Ciceri, Fabio; Cornelissen, Jan; Sanz, Jaime; Spyridonidis, Alexandros; Lanza, Francesco; Nagler, Arnon; Mohty, Mohamad
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/936853
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact